NeutriSci International Inc.

NeutriSci International Inc.

November 26, 2015 09:00 ET

NeutriSci Completes Oversubscribed $2.3 Million Private Placement

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov. 26, 2015) - NeutriSci International Inc. (the "Company" or "NeutriSci") (TSX VENTURE:NU) is pleased to announce that it has closed an oversubscribed non-brokered private placement (the "Placement") previously announced on October 20, 2015, for aggregate gross proceeds of $2,342,340. The Placement was increased from an initial amount of $2 million due to strong investor demand.

Glen Rehman President of NeutriSci, stated: "This oversubscribed financing is an overwhelming endorsement for the Company's NeuEnergy product offering, and our growth strategy to increase shareholder value. The proceeds of this financing will be integral for the ongoing marketing and distribution of NeuEnergy."

The Placement consisted of 13,013,000 units (the "Units") of the Company at a price of $0.18 per Unit. Each Unit consists of one common share of the Company and one common share purchase warrant, entitling the holder to acquire an additional common share of the Company at a price of $0.25 until November 25, 2017.

In connection with the Placement, the Company paid a cash commission totaling $127,411, and issued finder's warrants to purchase 707,840 Units. Each finder's warrant entitles the holder to acquire a Unit, at a price of $0.18 per Unit. All securities issued in connection with the Placement are subject to a hold period expiring March 26, 2016.

Proceeds of the Placement will be used to build inventory and for marketing and advertising programs related to NeuEnergy™, and for general corporate purposes.

On Behalf of the Board of Directors of NEUTRISCI INTERNATIONAL INC.

Glen Rehman, President

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

About NeutriSci International Inc.: NeutriSci specializes in the innovation, production and formulation of nutraceutical products. Established in 2009, NeutriSci has focused on the development of several breakthrough nutraceutical products with an initial focus on areas such as heart and cholesterol health, sleep deprivation therapies, immune defense as well as men's prostate and sexual health. NeutriSci continues to build strong relationships and distribution channels for its BluScience™ and NeuEnergy™ products with retailers throughout the United States. NeutriSci is focusing efforts in strengthening sustainable sales models with Convenience, Chain Drug, Mass Market and Supermarket retailers. For more information, visit

Contact Information